BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
about
Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioIntradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.Efficient RNA interference in patients' acute lymphoblastic leukemia cells amplified as xenografts in mice.Development and dynamics of robust T-cell responses to CML under imatinib treatmentThe biological basis for immunotherapy in patients with chronic myelogenous leukemia.SEA antagonizes the imatinib-meditated inhibitory effects on T cell activation via the TCR signaling pathwayImatinib induces H2AX phosphorylation and apoptosis in chronic myelogenous leukemia cells in vitro via caspase-3/Mst1 pathway.Immunotherapy of chronic myeloid leukemia: present state and future prospects.Immunomodulatory effects of anti-angiogenic drugs.Antigens in chronic myeloid leukemia: implications for vaccine development.Peptide vaccines for hematological malignancies: a missed promise?Immunology of chronic myeloid leukemia: current concepts and future goals.Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.Alantolactone inhibits growth of K562/adriamycin cells by downregulating Bcr/Abl and P-glycoprotein expression.The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.A novel mutation of SETBP1 in atypical chronic myeloid leukemia transformed from acute myelomonocytic leukemia.Immune modulation by molecular cancer targets and targeted therapies: Rationale for novel combination strategiesGene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen.H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib.Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides.The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors.
P2860
Q33526746-6C6A70BD-8729-4818-BC64-855CBC35BC7DQ34202277-F57D3FE9-04B5-4334-A93B-7697B64C08EAQ34994511-1504FF73-D381-42A0-AF4F-8B766D789594Q35950948-6FFA59D7-9ECB-44B7-B41B-93F214E8ABC3Q36677315-0E4A980B-416B-4D44-B0F5-2CD5E92E5C97Q37428671-F3C1A212-AD43-4E73-B6D6-FAD00D402BBEQ37541654-140F5B89-C1BD-4436-8222-BD62E9661DC9Q37729966-EE8844BB-09E8-4785-A762-101D7FDDB92CQ37773256-72A418CC-2507-4920-986D-745084AE2818Q37847051-A4C23710-1142-4B57-A6C9-C2DD07F3F28DQ37950233-4A6771A5-1E70-42E9-A3C3-3295749B6389Q38176546-282E96B8-7C55-4B69-A81A-5ABA97656EDDQ38366539-5BA0D895-8B44-4220-9BF4-7C8E37EBBC64Q38866390-06958368-8A74-4B23-88F8-69C919965315Q39188625-72FCB143-2E01-474C-8512-11782C32AAD8Q40217698-13B95181-F160-4BF5-84C1-09DA4D17D303Q40382581-AB3B78E8-9006-49A7-9B77-E36E6E681A3BQ40725420-A0B79626-D93E-47AE-9048-93E3F2401E67Q41835981-9B79DE6F-0217-46B8-86E5-E6CD03C5392FQ43143675-5779C8C5-39CB-406E-9DC0-B97F377DFBD4Q43572027-BA36BC4B-F63C-450B-8F8F-374414853F48Q46859831-2D25C7F2-1DCF-4CCB-9171-C02B8A2C332EQ54564968-4053317D-DD29-46FC-8B7B-929B0C96C4DF
P2860
BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
BCR-ABL activity is critical f ...... ic myelogenous leukemia cells.
@en
type
label
BCR-ABL activity is critical f ...... ic myelogenous leukemia cells.
@en
prefLabel
BCR-ABL activity is critical f ...... ic myelogenous leukemia cells.
@en
P2093
P1433
P1476
BCR-ABL activity is critical f ...... ic myelogenous leukemia cells.
@en
P2093
Anita Bringmann
Daniela Werth
Frank Grünebach
Karin von Schwarzenberg
Katharina M Brauer
Lothar Kanz
Peter Brossart
P304
P356
10.1158/0008-5472.CAN-07-0302
P407
P577
2007-06-01T00:00:00Z